Zusammenfassung
Grundlage der Behandlung der Osteoporose sind nichtmedikamentöse Maßnahmen und eine ausreichende Zufuhr von Calcium und Vitamin D als Basistherapie (Rizzoli et al. 2008). Bei niedrigem Frakturrisiko reichen sie zur Prophylaxe von osteoporotischen Frakturen aus. Ab einem 10-Jahresfrakturrisiko von 30% ist eine spezifische Osteoporosetherapie indiziert (Dachverband Osteologie 2014).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
Literatur
Arzneimittelkommission der Deutschen Ärzteschaft (2008): Empfehlungen zur Therapie und Prophylaxe der Osteoporose. Arzneiverordnung in der Praxis (Sonderheft 34S), 2. Auflage. Im Internet: www.akdae.de/35/83_Osteoporose_2008_2Auflage.pdf
Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drueke TB, Goodman WG (2004): Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350: 1516–1525
Bolland MJ, Grey A, Reid IR (2013): Calcium supplements and cardiovascular risk: 5 years on. Ther Adv Drug Saf 4: 199–210
Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA; Alendronate Phase III Osteoporosis Treatment Study Group (2004): Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350: 1189–1199
Brown JE, Coleman RE (2012): Denosumab in patients with cancer-a surgical strike against the osteoclast. Nat Rev Clin Oncol 9: 110–118
Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C; FREEDOM Trial (2009): Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361: 756–765
Dachverband Osteologie (2014): Prophylaxe, Diagnostik und Therapie der Osteoporose bei Männern ab dem 60. Lebensjahr und bei postmenopausalen Frauen. S3-Leitlinie des Dachverbands der Deutschsprachigen Wissenschaftlichen Osteologischen Gesellschaften e.V. – Kurzfassung und Langfassung. Internet: http://www.dv-osteologie.org/dvo_leitlinien/osteoporose-leitlinie-2014
Drüeke TB (2007): Lanthanum carbonate as a first-line phosphate binder: the „cons”. Semin Dial 20: 329–332
Edwards BJ, Sun M, West DP, Guindani M, Lin YH, Lu H, Hu M, Barcenas C, Bird J, Feng C, Saraykar S, Tripathy D, Hortobagyi GN, Gagel R, Murphy WA (2016): Incidence of atypical femur fractures in cancer patients: The MD Anderson Cancer Center Experience. J Bone Miner Res 31: 1569–1576
Favia G, Pilolli GP, Maiorano E (2009): Histologic and histomorphometric features of bisphosphonate-related osteonecrosis of the jaws: an analysis of 31 cases with confocal laser scanning microscopy. Bone 45: 406–413
Food and Drug Administration (2013): FDA Drug Safety Communication: Pediatric clinical studies of Sensipar (cinacalcet hydrochloride) suspended after report of death. Internet: http://www.fda.gov/Drugs/DrugSafety/ucm340551.htm
Jackson RD, LaCroix AZ, Gass M, Wallace RB, Robbins J, Lewis CE et al.; Women’s Health Initiative Investigators (2006): Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 354: 669–683
Lamy O (2012): Knochenanabole Therapie mit Teriparatid. Ther Umsch 69: 187–191
Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JP, Pieger CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S; HORIZON Recurrent Fracture Trial (2007): Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357: 1799–1810
Malberti F (2013): Hyperphosphataemia: treatment options. Drugs 73: 673–688
Manns B, Klarenbach S, Lee H, Culleton B, Shrive F, Tonelli M (2007): Economic evaluation of sevelamer in patients with end-stage renal disease. Nephrol Dial Transplant 22: 2867–2878
Navaneethan SD, Palmer SC, Vecchio M, Craig JC, Elder GJ, Strippoli GF (2011): Phosphate binders for preventing and treating bone disease in chronic kidney disease patients. Cochrane Database Syst Rev. 2011 Feb 16; (2): CD006023
NIH Consensus Conference (1994): Optimal calcium intake. JAMA 272: 1942–1948
Pazianas M, Compston J, Huang CL (2010): Atrial fibrillation and bisphosphonate therapy. J Bone Miner Res 25: 2–10.
Rachner TD, Khosla S, Hofbauer LC (2011): Osteoporosis: now and the future. Lancet 377: 1276–1287
Rizzoli R, Boonen S, Brandi ML, Burlet N, Delmas P, Reginster JY (2008): The role of calcium and vitamin D in the management of osteoporosis. Bone 42: 246–249
Servier (2014): Neue eingeschränkte Indikation und Empfehlungen zu Kontrollen bei der Einnahme von Protelos (Strontiumranelat). Internet: http://www.akdae.de/Arzneimittelsicherheit/RHB/Archiv/2014/index.html
Servier (2017): Protelos®: Einstellung der Produktion ab August 2017. Internet: http://www.servier.de/news/protelosr-einstellung-der-produktion-ab-august-2017
Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster D, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Koval K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O’Keefe R, Papapoulos S, Sen HT, van der Meulen MC, Weinstein RS, Whyte M; American Society for Bone and Mineral Research (2010): Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 25: 2267–2294
Straub DA (2007): Calcium supplementation in clinical practice: a review of forms, doses, and indications. Nutr Clin Pract 22: 286–296
Suki W, Zabaneh R, CangianoJ, Reed J, Fischer D, Garrett L, Ling B, Chasan-Taber S, Dillon M, Blair A, Burke S (2006): A prospective, randomized trial assessing the impact on outcomes of sevelamer in dialysis patients. The DCOR trial. Nephrol Dial Transplant 21 (Suppl 4): 145–146
The EVOLVE Trial Investigators (2012): Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 367: 2482–2494
Wade SW, Curtis JR, Yu J, White J, Stolshek BS, Merinar C, Balasubramanian A, Kallich JD, Adams JL, Viswanathan HN (2012): Medication adherence and fracture risk among patients on bisphosphonate therapy in a large United States health plan. Bone 50: 870–875
Ziegler R (2002): Osteoporose: aktuelle Diagnostik und Therapie. Orthopädische Praxis 38: 570–577
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer-Verlag GmbH Germany
About this chapter
Cite this chapter
Kasperk, C., Ziegler, R. (2017). Osteoporosemittel. In: Schwabe, U., Paffrath, D., Ludwig, WD., Klauber, J. (eds) Arzneiverordnungs-Report 2017. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-54630-7_39
Download citation
DOI: https://doi.org/10.1007/978-3-662-54630-7_39
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-54629-1
Online ISBN: 978-3-662-54630-7
eBook Packages: Medicine (German Language)